Updated KDIGO Guideline for Managing Diabetes in Patients with Chronic Kidney Disease

Newer pharmaceuticals are recommended, but expedient real-world implementation might be difficult.

Sponsoring Organization: Kidney Disease: Improving Global Outcomes (KDIGO)

Background

Several years ago, KDIGO published a comprehensive guideline for managing diabetes in patients with chronic kidney disease (CKD; NEJM JW Gen Med Jan 15 2021 and Ann Intern Med 2021; 174:385). Because many new randomized trials have been published since, KDIGO has published an update that includes 13 graded recommendations and 52 “practice points” for clinicians. The updated guideline focuses particularly on sodium–glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and the nonsteroidal mineralocorticoid-receptor antagonist finerenone.

Key Recommendations

SGLT-2 inhibitors are recommended for patients with type 2 diab…

Reviewing Author

Daniel D. Dressler, MD, MSc, MHM, FACP

Disclosures

RoyaltiesMcGraw-Hill; Elsevier

Editorial BoardsMedical Clinics of North America; Caribbean Medical Journal International Advisory Panel (2021–2026)